In the preclinical program, ANA598 was well tolerated at all doses tested in 28-day GLP
toxicology studies. In September 2008, Anadys initiated long-term, chronic
toxicology studies of ANA598.
If ANA598 is successful in early stage development, the Company anticipates completion of the clinical, toxicology and manufacturing activities required to initiate Phase II studies of ANA598 in combination with current standard of care in mid-2009.
Webcast of Conference Call
http://finance.yahoo.